Transcode Therapeutics Inc
RNAZ
NASDAQ
Biotechnology
$3.28
USD
-0.20 (-5.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.68M
Volume 40.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-40.36M
TTM
-58.2%
YoY
Operating Cash Flow
$-21.40M
TTM
-71.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.0 | 1.7 | 1.4 | 1.8 | 2.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 8.8 | 0.0 |
Total Operating Expenses | 3.2 | 4.2 | 4.6 | 16.0 | 17.8 |
Operating Income | -3.2 | -4.2 | -4.6 | -16.0 | -17.8 |
EBITDA | -3.2 | -4.2 | -4.6 | -7.2 | -17.7 |
Other Income / Expense | -9.3 | -0.1 | -0.3 | 2.7 | -0.0 |
Total Other Income / Expense | -8.9 | -0.1 | -0.3 | 2.8 | 0.2 |
Income Before Income Taxes | -12.1 | -4.3 | -4.9 | -13.2 | -17.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 |
Net Income | -12.1 | -4.3 | -4.9 | -13.4 | -17.8 |
Consolidated Net Income / Loss | -12.1 | -4.3 | -4.9 | -13.4 | -17.8 |
Net Income Attributable to Common Shareholders | -12.1 | -4.3 | -4.9 | -15.1 | -19.5 |
Basic EPS | -$70.16 | -$5.13 | -$5.82 | -$16.38 | -$21.28 |
Diluted EPS | -$70.16 | -$5.13 | -$5.82 | -$16.38 | -$21.28 |
Basic Shares Outstanding | 0.2M | 0.8M | 0.8M | 0.9M | 0.9M |
Diluted Shares Outstanding | 0.2M | 0.8M | 0.8M | 0.9M | 0.9M |